Search Results - "Ong, Voon H."

Using Autoantibodies and Cutaneous Subset to Develop Outcome‐Based Disease Classification in Systemic Sclerosis by Nihtyanova, Svetlana I., Sari, Alper, Harvey, Jennifer C., Leslie, Anna, Derrett‐Smith, Emma C., Fonseca, Carmen, Ong, Voon H., Denton, Christopher P.

“…Objective To describe the associations between autoantibodies, clinical presentation, and outcomes among patients with systemic sclerosis (SSc) in order to…”
Get full text

Prediction of Pulmonary Complications and Long‐Term Survival in Systemic Sclerosis by Nihtyanova, Svetlana I., Schreiber, Benjamin E., Ong, Voon H., Rosenberg, Daniel, Moinzadeh, Pia, Coghlan, J. Gerrard, Wells, Athol U., Denton, Christopher P.

“…Objective To assess survival and incidence of organ‐based complications in a large single‐center cohort of unselected systemic sclerosis (SSc) patients, and to…”
Get full text

Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis by Khan, Korsa, Xu, Shiwen, Nihtyanova, Svetlana, Derrett-Smith, Emma, Abraham, David, Denton, Christopher P, Ong, Voon H

“…To determine the potential clinical and pathological significance of altered expression of interleukin 6 (IL-6) in systemic sclerosis (SSc). Serum IL-6 and…”
Get more information

Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma by Moinzadeh, Pia, Fonseca, Carmen, Hellmich, Martin, Shah, Ami A, Chighizola, Cecilia, Denton, Christopher P, Ong, Voon H

“…We assessed the profile and frequency of malignancy subtypes in a large single-centre UK cohort for patients with scleroderma (systemic sclerosis; SSc). We…”
Get full text

The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index by Valentini, Gabriele, Iudici, Michele, Walker, Ulrich A, Jaeger, Veronika K, Baron, Murray, Carreira, Patricia, Czirják, László, Denton, Christopher P, Distler, Oliver, Hachulla, Eric, Herrick, Ariane L, Kowal-Bielecka, Otylia, Pope, Janet, Müller-Ladner, Ulf, Riemekasten, Gabriela, Avouac, Jerome, Frerix, Marc, Jordan, Suzana, Minier, Tünde, Siegert, Elise, Ong, Voon H, Vettori, Serena, Allanore, Yannick

“…Validity of European Scleroderma Study Group (EScSG) activity indexes currently used to assess disease activity in systemic sclerosis (SSc) has been…”
Get more information

Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis by Hughes, Michael, Ong, Voon H, Anderson, Marina E, Hall, Frances, Moinzadeh, Pia, Griffiths, Bridget, Baildam, Eileen, Denton, Christopher P, Herrick, Ariane L

“…Digital vasculopathy (comprising RP, digital ulceration and critical digital ischaemia) is responsible for much of the pain and disability experienced by…”
Get full text

Dynamic Prediction of Pulmonary Hypertension in Systemic Sclerosis Using Landmark Analysis by Nihtyanova, Svetlana I., Schreiber, Benjamin E., Ong, Voon H., Wells, Athol U., Coghlan, John G., Denton, Christopher P.

“…Objective Pulmonary hypertension (PH) is a serious complication of systemic sclerosis (SSc). In this study, we explored the prediction of short‐term risk for…”
Get full text

Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis by Clark, Kristina Elizabeth Neergaard, Campochiaro, Corrado, Csomor, Eszter, Taylor, Adam, Nevin, Katherine, Galwey, Nicholas, Morse, Mary A, Singh, Jennifer, Teo, Yee Voan, Ong, Voon H, Derrett-Smith, Emma, Wisniacki, Nicolas, Flint, Shaun M, Denton, Christopher P

“…Clinical heterogeneity is a cardinal feature of systemic sclerosis (SSc). Hallmark SSc autoantibodies are central to diagnosis and associate with distinct…”
Get more information

Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes by Clark, Kristina E. N., Campochiaro, Corrado, Host, Lauren V., Sari, Alper, Harvey, Jennifer, Denton, Christopher P., Ong, Voon H.

“…Systemic sclerosis (SSc) is characterized by the presence of SSc-specific or SSc-associated antibodies (SSc-Abs): anti-topoisomerase I (ATA), anti-centromere…”
Get full text

Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial by Stern, Edward P, Host, Lauren V, Wanjiku, Ivy, Escott, K Jane, Gilmour, Peter S, Ochiel, Rachel, Unwin, Robert, Burns, Aine, Ong, Voon H, Cadiou, Helen, O'Keeffe, Aidan G, Denton, Christopher P

“…We report results from a phase II randomised placebo-controlled trial assessing zibotentan, a highly selective endothelin receptor antagonist (ERA), in chronic…”
Get full text

Real-world experience of tocilizumab in systemic sclerosis: potential benefit on lung function for anti-topoisomerase-positive patients by Suleman, Yasir, Clark, Kristina E N, Cole, Alice R, Ong, Voon H, Denton, Christopher P

Get full text

Clinical and Serological Hallmarks of Systemic Sclerosis Overlap Syndromes by PAKOZDI, Angela, NIHTYANOVA, Svetlana, MOINZADEH, Pia, ONG, Voon H, BLACK, Carol M, DENTON, Christopher P

“…To determine the prevalence of systemic sclerosis (SSc) overlap syndrome and autoantibody profile in a large single-center cohort. SSc diagnoses, subsets, and…”
Get full text

Dysregulated B cell function and disease pathogenesis in systemic sclerosis by Beesley, Claire F, Goldman, Nina R, Taher, Taher E, Denton, Christopher P, Abraham, David J, Mageed, Rizgar A, Ong, Voon H

“…Systemic sclerosis (SSc) is a complex, immune-mediated rheumatic disease characterised by excessive extracellular matrix deposition in the skin and internal…”
Get full text

Challenges in evidence-based therapy for systemic sclerosis associated interstitial lung disease by Denton, Christopher P, Ong, Voon H

Get full text

The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis by Derrett-Smith, Emma, Clark, Kristina E N, Shiwen, Xu, Abraham, David J, Hoyles, Rachel K, Lacombe, Olivier, Broqua, Pierre, Junien, Jean Louis, Konstantinova, Irena, Ong, Voon H, Denton, Christopher P

“…The TβRII∆k-fib transgenic (TG) mouse model of scleroderma replicates key fibrotic and vasculopathic complications of systemic sclerosis through…”
Get full text

News and failures from recent treatment trials in systemic sclerosis by Denton, Christopher P., Yee, Philip, Ong, Voon H.

“…There have been many recent trials in systemic sclerosis (SSc) that have explored treatment for skin or lung. Some have been encouraging, but there has also…”
Get full text

Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature by Derrett-Smith, Emma C, Martyanov, Viktor, Chighizola, Cecilia B, Moinzadeh, Pia, Campochiaro, Corrado, Khan, Korsa, Wood, Tammara A, Meroni, Pier Luigi, Abraham, David J, Ong, Voon H, Lafyatis, Robert, Whitfield, Michael L, Denton, Christopher P

“…Systemic sclerosis (SSc; scleroderma) is an uncommon autoimmune rheumatic disease characterised by autoimmunity, vasculopathy and fibrosis. Gene expression…”
Get full text

Renal Disease and Systemic Sclerosis: an Update on Scleroderma Renal Crisis by Cole, Alice, Ong, Voon H., Denton, Christopher P.

“…Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis (SSc) with a mortality of 20% at 6 months. Once the leading cause of…”
Get full text

Three Cases of Systemic Sclerosis Within One Family With Different Antibodies and Clinical Features by Spierings, Julia, Ong, Voon H, Denton, Christopher P

Get full text

The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review by Chighizola, Cecilia Beatrice, Ong, Voon H., Meroni, Pier Luigi

“…Cyclosporine A, an inhibitor of calcineurin, exerts an immunomodulator action interfering with T cell activation. Even though novel therapeutic tools have…”
Get full text